Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lava Therapeutics N V has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner in 1 distinct art unit, which limits the current prosecution activity to a single technical channel. For a company in the biotechnology sector, this concentration under 1 distinct examiner means that the path to allowance is governed by the specific scientific interpretations of one individual.
KIM, YUNSOO serves as the busiest examiner with 1 pending office action. Because there is only 1 distinct examiner for the entire portfolio's pending actions, the company's immediate outcomes depend on the individual examination style of this specific official. The 1 pending office action represents the totality of the firm's current engagement with the patent office, making the relationship with KIM, YUNSOO a critical component of their intellectual property strategy.
Navigating the Biotechnology & Pharmaceuticals field often involves complex technical hurdles, and with 1 distinct art unit involved, the company is subject to the specific internal policies of that unit. Practitioners should focus on the specific requirements of KIM, YUNSOO to ensure that the 1 pending office action is resolved efficiently. The lack of multiple pending actions means that the firm can dedicate its full attention to this single examination process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332165 | ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332165 | ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18332165 | ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS | KIM, YUNSOO | 1641 | §101DP | Non-Final OA | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial